Unknown

Dataset Information

0

The structure of the metallo-?-lactamase VIM-2 in complex with a triazolylthioacetamide inhibitor.


ABSTRACT: The increasing number of pathogens expressing metallo-?-lactamases (MBLs), and in this way achieving resistance to ?-lactam antibiotics, is a significant threat to global public health. A promising strategy to treat such resistant pathogens is the co-administration of MBL inhibitors together with ?-lactam antibiotics. However, an MBL inhibitor suitable for clinical use has not yet been identified. Verona integron-encoded metallo-?-lactamase 2 (VIM-2) is a widespread MBL with a broad substrate spectrum and hence is an interesting drug target for the treatment of ?-lactam-resistant infections. In this study, three triazolylthioacetamides were tested as inhibitors of VIM-2. One of the tested compounds showed clear inhibition of VIM-2, with an IC50 of 20?µM. The crystal structure of the inhibitor in complex with VIM-2 was obtained by DMSO-free co-crystallization and was solved at a resolution of 1.50?Å. To our knowledge, this is the first structure of a triazolylthioacetamide inhibitor in complex with an MBL. Analysis of the structure shows that the inhibitor binds to the two zinc ions in the active site of VIM-2 and revealed detailed information on the interactions involved. Furthermore, the crystal structure showed that binding of the inhibitor induced a conformational change of the conserved residue Trp87.

SUBMITTER: Christopeit T 

PROVIDER: S-EPMC5101582 | biostudies-literature | 2016 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

The structure of the metallo-β-lactamase VIM-2 in complex with a triazolylthioacetamide inhibitor.

Christopeit Tony T   Yang Ke Wu KW   Yang Shao Kang SK   Leiros Hanna Kirsti S HK  

Acta crystallographica. Section F, Structural biology communications 20161024 Pt 11


The increasing number of pathogens expressing metallo-β-lactamases (MBLs), and in this way achieving resistance to β-lactam antibiotics, is a significant threat to global public health. A promising strategy to treat such resistant pathogens is the co-administration of MBL inhibitors together with β-lactam antibiotics. However, an MBL inhibitor suitable for clinical use has not yet been identified. Verona integron-encoded metallo-β-lactamase 2 (VIM-2) is a widespread MBL with a broad substrate sp  ...[more]

Similar Datasets

| S-EPMC3373053 | biostudies-literature
| S-EPMC3088182 | biostudies-literature
| S-EPMC8830069 | biostudies-literature
| S-EPMC3020596 | biostudies-literature
| S-EPMC179807 | biostudies-literature
| S-EPMC2901175 | biostudies-literature
| S-EPMC1315972 | biostudies-literature
| S-EPMC8968847 | biostudies-literature
| S-EPMC2395088 | biostudies-literature